The wound care company Odinwell announces that the exercise period for TO 1 warrants ended on December 2 and resulted in just over 9.1 million warrants, corresponding to about 88 percent, being converted into the same number of shares.Odinwell now plans to convene an extraordinary general meeting to resolve on a directed new share issue of just over 1.3 million shares to the investors who guaranteed the proceeds. Through the exercise of the warrants, the company will receive approximately SEK 1.5 million and, if the issue is approved, may receive an additional approximately SEK 0.2 million, totaling about SEK 1.7 million before costs."We are very pleased with the confidence our shareholders have shown by participating in the exercise of series TO 1 subscription warrants. The capital now being contributed to Odinwell strengthens our financial position and gives us greater flexibility in our continued efforts to commercialize our solutions. We now look forward to continuing the development with full force and realizing the opportunities ahead of us," says CEO Marcus Andersson.TO 1 originates from a rights issue of units during the second quarter of this year.